---
title: "HISUN Pharmaceuticals and ShengZhao Pharmaceuticals jointly established a joint venture company to expand their international presence in the complex injectable drug field"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263431675.md"
description: "On October 30th, HISUN Pharmaceuticals and ShengZhao Pharmaceuticals held a cooperation signing ceremony in Taizhou, Zhejiang. According to the agreement, HISUN Pharmaceuticals and ShengZhao Pharmaceuticals will jointly invest in establishing a joint venture company in the Jiaojiang District of Taizhou City, focusing on the field of complex injectables. HISUN Pharmaceuticals plans to invest CNY 495 million for a 45% stake; ShengZhao Pharmaceuticals plans to invest CNY 605 million for a 55% stake. The joint venture will primarily engage in the research and development, production, and commercialization of 11 complex injectable products. In addition, HISUN Pharmaceuticals will have the priority cooperation rights for future related products from ShengZhao Pharmaceuticals"
datetime: "2025-10-30T05:52:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263431675.md)
  - [en](https://longbridge.com/en/news/263431675.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263431675.md)
---

# HISUN Pharmaceuticals and ShengZhao Pharmaceuticals jointly established a joint venture company to expand their international presence in the complex injectable drug field

On October 30th, HISUN Pharmaceuticals signed a cooperation agreement with ShengZhao Pharmaceuticals in Taizhou, Zhejiang. According to the agreement, HISUN Pharmaceuticals and ShengZhao Pharmaceuticals will jointly invest in establishing a joint venture company in the Jiaojiang District of Taizhou City, focusing on the field of complex injectable drugs. HISUN Pharmaceuticals plans to invest 495 million yuan for a 45% stake, while ShengZhao Pharmaceuticals plans to invest 605 million yuan for a 55% stake. The joint venture will primarily engage in the research and development, production, and commercialization of 11 complex injectable drug products. In addition, HISUN Pharmaceuticals will have the right of first cooperation for future related products from ShengZhao Pharmaceuticals

### Related Stocks

- [600267.CN](https://longbridge.com/en/quote/600267.CN.md)

## Related News & Research

- [15:30 ETTravis Manion Foundation to Honor 10,000 Military Heroes on Memorial Day Weekend Through "The Honor Project"](https://longbridge.com/en/news/287109444.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [HSA warns public against consuming herbal remedy containing potent steroid](https://longbridge.com/en/news/287022845.md)
- [Announcement from Eimskip: Seafarers’ Union of Iceland announces strike](https://longbridge.com/en/news/286679460.md)
- [02:50 ETPowerbox wprowadza na rynek serię wytrzymałych przetworników DC/DC do zastosowań w sektorze obronnym](https://longbridge.com/en/news/286867266.md)